Response to Intravenous N-Acetylcysteine Supplementation in Critically Ill Patients with COVID-19
Gamarra-Morales Y, Herrera-Quintana L, Molina-López J, Vázquez-Lorente H
Published in Nutrients
Methodology
Randomized controlled clinical trial of intravenous N-acetylcysteine versus standard care in ICU patients with COVID-19; clinical outcomes and redox/inflammatory biochemistry assessed
Key Findings
Intravenous NAC modified redox and inflammatory biochemistry in critically ill patients but did not produce clear clinical benefit on the trial's main clinical endpoints.
Conclusions
Boosting cysteine/glutathione substrate supply changes biochemical markers without reliably translating into clinical improvement in acute critical illness.
Limitations
Small ICU sample, open design, acute critical-illness setting not generalisable to healthy supplement users.
Supplements Studied
Administering N-acetylcysteine (NAC) could counteract the effect of free radicals, improving the clinical evolution of patients admitted to the Intensive Care Unit (ICU).
Outcomes Measured
Administering N-acetylcysteine (NAC) could counteract the effect of free radicals, improving the clinical evolution of patients admitted to the Intensive Care Unit (ICU).
Study Details
Access Study
Disclosures
Funding
Public/hospital research funding
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.